オプションチェーンは、Celularityの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Celularityの市場センチメントを評価します。.

Celularity (NASDAQ:CELU) 株価情報, オプションチェーン

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

News

Guidance

SENS

Senseonics Sees FY24 Revenue $22M Vs $22.182M Est.

DXC Technology Sees Q3 2025 Revenue $3.2B-$3.3B Vs $3.2B Est.; Sees Adj EPS $0.75-$0.80 Vs $0.72 Est.

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $1.965 million which missed the analyst consensus estimate of $5.420 million by 63.74 percent. This is a 56.60 percent decrease over sales of $4.528 million the same period last year.

Earnings

Earnings Misses

GEVO

Gevo Q3 2024 GAAP EPS $(0.09) Misses $(0.07) Estimate, Sales $1.965M Miss $5.420M Estimate

SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.00 million in sales this quarter. This is a 8.28 percent increase over sales of $9.23 million the same period last year.

SIGA

SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY

PODD

Insulet Raises FY24 Revenue Growth To Range Of 20% - 21% (Previously 16% -19%)

Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $4.300 million which beat the analyst consensus estimate of $4.078 million by 5.44 percent. This is a 29.47 percent decrease over sales of $6.097 million the same period last year.

Earnings Beats

Senseonics Holdings Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $4.300M Beat $4.078M Estimate

Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 175 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $35.409 million which beat the analyst consensus estimate of $35.013 million by 1.13 percent. This is a 2.97 percent decrease over sales of $36.494 million the same period last year.

EXFY

Expensify Q3 2024 Adj. EPS $0.06, Inline, Sales $35.409M Beat $35.013M Estimate

Business Outlook
Five9 provides guidance based on current market conditions and expectations. Five9 emphasizes that the guidance is subject to various important cautionary factors referenced in the section entitled "Forward-Looking Statements" below, including risks and uncertainties associated with ongoing impact of macroeconomic challenges.
<ul>
<li>For the full year 2024, Five9 now expects to report:
<ul>
<li>Revenue in the range of $1.030 to $1.031 billion.</li>
<li>GAAP net loss per share in the range of $(0.30) to $(0.23), assuming basic shares outstanding of approximately 74.5 million.</li>
<li>Non-GAAP net income per share in the range of $2.36 to $2.38, assuming diluted shares outstanding of approximately 75.0 million.</li>
</ul>
</li>
<li>For the fourth quarter of 2024, Five9 expects to report:
<ul>
<li>Revenue in the range of $267.0 to $268.0 million.</li>
<li>GAAP net income per share in the range of $0.03 to $0.08, assuming diluted shares outstanding of approximately 88.6 million.</li>
<li>Non-GAAP net income per share in the range of $0.69 to $0.71, assuming diluted shares outstanding of approximately 76.0 million.</li>
</ul>
</li>
</ul>
With respect to Five9's guidance as provided above, please refer to the "Reconciliation of GAAP Net Loss to Non-GAAP net income - Guidance" table for more details, including important assumptions upon which such guidance is based.

FIVN

Five9 Sees Q4 EPS $0.69-$0.71 Vs $0.68 Est.; Revenue $267M-$268M Vs $261.15M Est.; FY24 EPS $2.36-$2.38 Vs $2.27 Est.; Revenue $1.03B-$1.031B $1.02B Vs Est.

Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) lowers FY2024 sales outlook from $196.00 million-204.00 million to $186.00 million-189.00 million.

NRDY

Nerdy Lowers FY2024 Sales Guidance from $196.00M-204.00M to $186.00M-189.00M

Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) sees Q4 sales of $44.000 million-47.000 million vs $56.97 million estimate.

Nerdy Sees Q4 Sales $44.000M-47.000M vs $56.97M Est

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.03 by 2233.33 percent. The company reported quarterly sales of $55.307 million which beat the analyst consensus estimate of $41.927 million by 31.91 percent. This is a 96.58 percent increase over sales of $28.134 million the same period last year.

RIGL

Rigel Pharmaceuticals Q3 2024 GAAP EPS $0.70 Beats $0.03 Estimate, Sales $55.307M Beat $41.927M Estimate

Sweetgreen Sees FY24 Revenue $675M-$680M Vs $678.524M Est.

Alarm.com Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRM#NASDAQ">ALRM</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.49 by 26.53 percent. This is a 10.71 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $240.50 million which beat the analyst consensus estimate of $231.46 million by 3.90 percent. This is a 8.40 percent increase over sales of $221.85 million the same period last year.

ALRM

Alarm.com Holdings Q3 Adj $0.62 Beats $0.49 Estimate, Sales $240.50M Beat $231.46M Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.72 by 29.17 percent. The company reported quarterly sales of $3.24 billion which beat the analyst consensus estimate of $3.20 billion by 1.27 percent. This is a 5.68 percent decrease over sales of $3.44 billion the same period last year.

DXC Technology Q2 2025 Adj EPS $0.93 Beats $0.72 Estimate, Sales $3.24B Beat $3.20B Estimate

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(0.96) by 73.96 percent. The company reported quarterly sales of $32.500 million which beat the analyst consensus estimate of $32.086 million by 1.29 percent. This is a 30.07 percent decrease over sales of $46.478 million the same period last year.

CUTR

Cutera Q3 2024 Adj. EPS $(1.67) Misses $(0.96) Estimate, Sales $32.500M Beat $32.086M Estimate

Electric vehicle company Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) reported third-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Thursday.</a>
Here are the key highlights.
What Happened: Rivian announced third-quarter revenue of $874 million, which missed a Street consensus estimate of $1.00 billion, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company reported a loss of 99 cents per share, missing a Street consensus loss of 92 cents per share.
Operating expenses in the third quarter were $777 million, down from $963 million in the third quarter of the prior year.
Rivian had production of 13,157 vehicles in the third quarter and deliveries of 10,018 vehicles in the quarter. &nbsp;
"This quarter we have made progress against our key objectives and have seen meaningful progress on our Gen 2 R1 cost structure due to the new technologies incorporated into the vehicle and manufacturing process," Rivian CEO RJ Scaringe said.
The company announced a strategic supply agreement with LG Energy Solutions Thursday. The supply agreement will help power the company's next-generation midsize electric vehicle platform.
Rivian ended the third quarter with $6.74 billion in cash and cash equivalents, which includes $1 billion of an unsecured convertible note issued to Volkswagen International America, related to the joint venture with Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>). The note will automatically convert into shares of Rivian Class A stock on Dec. 1, 2024.
Read Also: <a href="https://www.benzinga.com/trading-ideas/previews/24/11/41817826/rivian-q3-earnings-preview-analyst-worries-about-demand-will-company-comment-on-2024-elect">Rivian Q3 Earnings Preview: Analyst Worries About Demand, Will Company Comment On 2024 Election Impact?</a>
What's Next: Rivian said it expects to reach positive gross profit in the fourth quarter with higher revenue per unit and improved fixed costs per unit.
The company said it is making progress on the R2 vehicle.
Rivian reaffirmed its 2024 production guidance of a range of 47,000 to 49,000 and a delivery outlook of 50,5000 to 52,000 vehicles for the full year.
EBITDA guidance ranged from a loss of $2.825 billion to $2.875 billion.
"We are excited about the future and our midsize SUV, R2, which we believe will be a fundamental driver of Rivian's growth. We're also looking forward to closing our proposed joint venture with Volkswagen Group, which is expected in the fourth quarter," Scaringe said.
RIVN Price Action: Rivian stock is up 3.2% to $10.38 in after-hours trading Thursday, versus a 52-week trading range of $8.26 to $24.61.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41814412/rivian-vs-lucid-which-ev-stock-has-the-edge-ahead-of-q3-earnings">Rivian Vs. Lucid: Which EV Stock Has The Edge Ahead Of Q3 Earnings?</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Rivian Q3 2024 Earnings Call &#x7C; $RIVN" width="500" height="281" src="https://www.youtube.com/embed/EWhgjRxRRlI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: rblfmr/Shutterstock.com

Movers

Trading Ideas

RIVN

VWAGY

Rivian Q3 Earnings Highlights: Revenue, EPS Miss, CEO Confident In Q4 Gross Profit, R2 Being 'Fundamental Driver' Of Growth

Management

RingCentral Appoints Abhey Lamba As Chief Financial Officer

SOLV

Solventum Raises 2024 Adjusted EPS Outlook From $6.30 - $6.50 To $6.50 -$6.65 (Est $6.38)

Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) affirms FY2024 sales outlook from $35.00 million-38.00 million to $35.00 million-38.00 million.

TKNO

Alpha Teknova Affirms FY2024 Sales Guidance from $35.00M-38.00M to $35.00M-38.00M

TASK

TaskUs Sees FY24 Revenue $988M-$990M Vs $967.360M Est; Sees Q4 Revenue $267.3M-$269.3M.

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Markets

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

ImmuCell

MiNK Therapeutics

Longeveron

Lantern Pharma

Lumos Pharma

Marker Therapeutics

NextCure

Ocean Biomedical

SAB Biotherapeutics

Surrozen

vTv Therapeutics Inc. - Class A Common Stock

Comments

Celularity

Celularity (CELU) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル